Haofeng Medtech

About Haofeng Medtech

Haofeng Medtech, officially known as Shanghai Haofeng Medical Technology Co., Ltd., was established in 2013 and operates as a specialized contract development and manufacturing organization (CDMO) for the medical device industry. The company is headquartered in Shanghai, China, and focuses on providing a comprehensive service chain for global medical device companies, particularly for Class III interventional devices. Under the leadership of Chairman Liu Chunjie, Haofeng Medtech has positioned itself as an integrated platform for smart equipment, components, and materials services. The firm employs over 200 professionals, including more than 60 engineers and R&D experts.

The company's business model is centered on being a dedicated CDMO partner, which means it supports other medical device companies through the entire product lifecycle, from initial research and development to post-market contract manufacturing, without competing with its end customers. Haofeng Medtech generates revenue by providing these specialized manufacturing and development services. Its clients are global medical device companies, with established partnerships in Europe, Latin America, and Southeast Asia. The company has secured significant venture capital, including an early-stage VC round in May 2022, a Series A in November 2023, and a Pre-B round of nearly $14 million in January 2025, led by Zhuhai High-tech Venture Capital with support from existing investor Cenova Capital. These funds are allocated to expand production capacity and enhance its global presence.

Haofeng Medtech's service and product portfolio is structured around three main platforms: equipment, components, and energy. The equipment division provides intelligent manufacturing equipment and complete solutions, such as balloon and catheter production lines. The components platform offers contract development and manufacturing for devices like balloon catheters, interventional catheters, and guidewires. Through its wholly-owned subsidiary M-Duke, it serves the high-end interventional device market, handling everything from prototyping to large-scale production. The energy division focuses on active medical devices for applications like radiofrequency and cryoablation. The company operates out of extensive GMP-certified cleanroom facilities in Shanghai and is expanding with a new production base in Zhuhai. Its capabilities cover a wide range of applications, including neural, peripheral, and coronary interventions, as well as structural heart and electrophysiology devices.